Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

PHASE3CompletedINTERVENTIONAL

Enrollment

657

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2007

Conditions

DyslipidemiaCoronary Heart DiseaseMixed Dyslipidemia

Interventions

DRUG

ABT-335

135 mg, daily, 12 weeks

DRUG

Simvastatin

daily, 12 weeks, see Arm Description for dosage information

DRUG

Placebo

Daily, 12 weeks, see Arm Description for placebo information

Trial Locations (1)

Global Medical Information, North Chicago